Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Generic Name
- Recombinant Human Granulocyte Colony-stimulating Factor（rhG-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.各种原因引起的中性粒细胞减少证，如恶性肿瘤和白血病化疗与放疗引起的中性粒细胞减少、造血干/祖细胞移植后髓系造血功能的受抑及延迟植活鱼移植排斥；
2.周围血造血干/祖细胞移植前的干/祖细胞动员等；
3.骨髓增生异常综合征（MDS）、再生障碍性贫血伴发的中性粒细胞减少，先天性、特发性、周期性中性粒细胞减少症，但远期疗效不肯定；
4.各种严重感染，包括艾滋病及并发的感染；
5.抗艾滋病药物引起的中性粒细胞减少症也可应用。
- Associated Conditions
- -
- Associated Therapies
- -
Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Ain Shams Maternity Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03023774
PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Peking University
- Target Recruit Count
- 96
- Registration Number
- NCT02905942
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 324
- Registration Number
- NCT02816164
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 458
- Registration Number
- NCT02816112
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-06-20
- Target Recruit Count
- 215
- Registration Number
- NCT02805153
Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02682953
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT02489500
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Use Art-assist and Neupogen to Treat Chronic Limb Ischemia
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT02408991
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Tandem Auto-Allo Transplant for Lymphoma
- Conditions
- Interventions
- Drug: Busulfan (conditioning for AUTO transplant)Drug: Etoposide (conditioning for AUTO transplant)Drug: Cyclophosphamide (conditioning for AUTO transplant)Drug: Mesna (prior to AUTO transplant)Other: autologous (auto) peripheral blood stem cell transplantationDrug: NeupogenDrug: Fludarabine (conditioning for ALLO Transplant)Drug: Busulfan (conditioning for ALLO Transplant)Other: non-myeloablative allogeneic (allo) transplantDrug: TacrolimusDrug: SirolimusDrug: Methotrexate
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT01181271
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.